Connect with us

Featured Stocks

Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?

Published

on

Planet 13 stock

The marijuana stocks universe presents a variety of choices. But not all choices are great. You want to put your money in a marijuana company with a strong competitive advantage, great growth potential, and solid financials. If you are looking for a great pot stock to buy heading into 2020, Planet 13 stock (CNSX:PLTH) (OTCMKTS:PLNHF) is a strong candidate.

About Planet 13 stock

For investors who may be learning about Planet 13 Holdings for the first time, this is a vertically-integrated marijuana business. It is one of the leading marijuana companies in the Nevada market. Planet 13 Holdings is engaged in the cultivation, processing, and retail of marijuana products and it already has several marijuana brands to its credit. It operates the largest marijuana retail outlet in the world.

What you should know about Planet 13 stock

For marijuana sector in general, 2019 has generally been a rough year. Many marijuana stocks have dropped to multiyear lows. As the charts show, Planet 13 Holdings stock has been through a lot of ups and downs this year. Still, those swings have delivered decent returns for investors who know how to play stocks like Planet 13 Holdings in volatile periods.

Presently, Planet 13 Holdings stock is trading at $1.64. The stock began the year at $1.00. It jumped to $1.64 in February, thereby returning nearly 65% in space of a few weeks. There was a period of profit-taking following the January surge, resulting in the stock coming down to $1.25. From there, it began moving up again, reaching its 2019 peak of $2.62 in April and delivering a return of 110% to investors who picked up the stock at its previous low.

Why Planet 13 stock is poised for greater highs

Stock up and down moves typically create short-term profit opportunities for investors who can play a volatile stock market to their advantage. But Planet 13 Holdings is more than a short-term profit stock. Here are three reasons you may want to add Planet 13 Holdings stock to your portfolio going into 2020.

  • No other company except Planet 13 Holdings owns and operates the world’s largest marijuana retail outlet

In November 2018, Planet 13 Holdings opened SuperStore, a marijuana retail complex just west of Las Vegas strip, Nevada. Planet 13’s SuperStore is a 112,000 square feet facility that also hosts a restaurant in addition to marijuana shop and on-site marijuana processing unit.

Sales have been booming at the SuperStore. Through the facility alone Planet 13 fills about 10% of all marijuana sales in the entire state of Nevada. Through its SuperStore facility, Planet 13 Holdings has positioned itself well to take full advantage of the growing demand for marijuana products in Nevada. Nevada’s marijuana market, comprising sales of medical and recreational marijuana products, generated $580 million in revenue in 2018, ArcView Market Research and BDS Analytics estimates show. The market will grow to $795 million by 2022.

Having seen the early success of SuperStore, Planet 13 plans to open another world-class marijuana retail complex. It plans to open what would be the world’s second-largest marijuana retail outlet in Santa Ana, California, next year. The Santa Ana complex will sit just a few miles from busy sites such as the South Coast Plaza Mall and Disneyland. California has one of the fastest-growing marijuana markets. California’s marijuana sales hit $2.5 billion in 2018 and will jump to $5.6 billion by 2022.

  • Planet 13 Holdings is well-capitalized to pursue its development dreams

Presently, credit funding opportunities are limited for marijuana companies in the United States. That is because big banks have generally shunned doing business with marijuana companies for fear of running afoul of federal regulations.

Congress is working on a solution to this challenge. However, Planet 13 Holdings isn’t waiting for Congress to pass laws that would make obtaining loans from big banks easy before it can develop its business and create value for shareholders. Planet 13 is one of the few well-capitalized marijuana companies. The company disclosed in its third-quarter report that its current capital position allows it to complete all its growth initiatives.

  • Planet 13 Holdings is a marijuana company that investors can trust

Investors may not have any doubts regarding financial services or technology stocks because these are well-established industries with clear regulations. But marijuana is different. The industry is new and regulation is far from complete, especially considering that marijuana remains federally illegal in the United States.

Planet 13 Holdings is doing a great job to overcome doubts that investors may have about its business. Every few weeks, Planet 13 issues a press release to update investors on its operations. This past November, for instance, Planet 13 issued five press releases. That ensures that investors stay up-to-date with the directions the company is taking and can make informed investment decisions. To win over more investors, building trust is important and Planet 13 does just that.

Bottom line

Planet 13 stock stands out in the marijuana universe as a stock that can deliver excellent returns. Now trading close to its multiyear lows, Planet 13 stock looks primed for a big breakout.

We will be updating our subscribers as soon as we know more. For the latest updates on Planet 13 stock, sign up below!

Disclosure: We have no position in Planet 13 stock and have not been compensated for this article.

Featured Stocks

Forget APHA and ACB, Buy GTBIF and TCNNF

Published

on

GTBIF TCNNF

There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).

On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.

There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.

GTBIF

Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.

Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.

The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…

Continue Reading

Featured Stocks

Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity

Published

on

OTCMKTS:DECN

Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.

OTCMKTS:DECN Price Analysis

The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.

OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.

DECN Daily Chart

Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.

About OTCMKTS:DECN

Decision Diagnostics bills itself…

Continue Reading

Featured Stocks

Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?

Published

on

CytoDyn

CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.

The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.

Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.

About CytoDyn

CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.

Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.

CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment

CytoDyn’s lead drug candidate leronlimab (PRO 140)…

Continue Reading

MJ Stocks